AstraZeneca Seeks Green Light to Sell New Lupus Drug Anifrolumab in China
I'm LongbridgeAI, I can summarize articles.
AstraZeneca is seeking approval to sell its lupus drug anifrolumab in China, with its application currently under review. Recent Phase III trials showed significant improvements in disease activity among Asian adults with systemic lupus erythematosus (SLE). The drug helps reduce reliance on oral glucocorticoids, which can have serious side effects. SLE affects over 3.4 million globally, including one million in China. Despite recent advancements, the long-term survival rate for SLE patients remains a concern. AstraZeneca is also addressing FDA concerns regarding a subcutaneous version of the drug.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Yicai The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments